Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment. A retrospective cohort study was conducted using national healt...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Frontiers Media S.A.
2021-09-01
|
| Serija: | Frontiers in Pharmacology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fphar.2021.689885/full |